Alzheon Raises $100 Million in Series E Funding for Alzheimers Disease Treatment
Alzheon, Inc. is a clinicalstage biopharmaceutical company focused on developing therapies for Alzheimers disease and other neurodegenerative disorders. The companys lead candidate, ALZ801, is an oral diseasemodifying therapy currently in Phase 3 development for the treatment of early Alzheimers disease.
The $100 million raised in the Series E funding round will be used to support the completion of Alzheons pivotal Phase 3 clinical trials for ALZ801 and prepare for potential commercialization. The funding will also help advance the companys innovative science and technology with the goal of transforming the standard of care for Alzheimers patients.
The funding round was led by Alerce Medical Technology Partners, a prominent investor specializing in latestage lifesaving drugs and technologies. Alzheons Series E financing round garnered support from institutional and private investors, reflecting confidence in the companys novel therapeutic approach and drug candidate.
Alzheons ALZ801 has shown promising results in blocking the formation of neurotoxic beta amyloid oligomers, with favorable safety profiles in clinical studies. The companys focus on precision medicine, particularly targeting APOE4/4 homozygotes, has the potential to revolutionize Alzheimers treatment by slowing disease progression.
The successful funding round ensures Alzheons financial stability to complete its Phase 3 program and potentially bring ALZ801 to market by 2025. The companys commitment to addressing the underlying pathology of neurodegeneration through innovative drug development positions it as a key player in the Alzheimers treatment landscape.
Article
